- Amarantus Bioscience's (AMBS) Eltoprazine treatment for adults with ADHD met its primary target in a Phase IIa trial of 47 patients and demonstrated 25% greater efficacy vs a placebo.
- No serious adverse events took place, while most of the side effects were "mild of moderate." Still, only 36 subjects completed the study.
- Amarantus is reviewing it options for the further advancement of its ADHD program, including business-development possibilities as the company prepares to up-list to a national stock exchange. (PR)
Amarantus' ADHD drug performs well in Phase IIa study
Feb 4 2014, 09:32 ET